Explore 3 Stock Ideas & Industry Insights Download Free Report

News

Roth Capital Upgrades Electronic Arts (NASDAQ:EA) to Buy, Hikes Target to USD 185

Roth Capital has upgradedElectronic Arts Inc. (NASDAQ:EA)fromNeutraltoBuy, raising its 12-month price target toUSD185, up from the previous USD175. The broker attributes the upgrade to growing confidence in EA’s execution capabilities and the potential fordouble-digit earnings growth over the next three fiscal years.

Team Kalkine | 25 June 2025

Citizens JMP Upgrades Capital Southwest (NASDAQ:CSWC) to Market Outperform

Citizens JMP Securities has upgradedCapital Southwest Corporation (NASDAQ:CSWC)fromMarket PerformtoMarket Outperform, assigning a newprice target of USD25.00. The rating change comes in response to what the research firm described as “one of the best quarterly results” from the business development company (BDC) in the first …

Team Kalkine | 25 June 2025

U.S. Markets Daily Wrap-Up: Stocks Rally, Oil Rebounds, and Fed Policy in Focus

Index Update:U.S. stocks rallied on Tuesday, with the S&P 500 and Nasdaq nearing record highs amid easing geopolitical tensions as a ceasefire between Israel and Iran appeared to hold. The Dow also posted strong gains. Oil prices extended their decline, falling nearly 20% from …

Team Kalkine | 25 June 2025

ECARX (Nasdaq: ECX) Expands into Robotics with Lidar Partnership; Targets Mass Production by 2026

ECARX Holdings Inc. (Nasdaq: ECX), known for its automotive intelligence systems, announced a strategic partnership with a leading global developer of robotic lawn mowers to deploy its proprietary solid-state lidar technology in non-automotive applications. The agreement represents a notable pivot for ECARX as it …

Team Kalkine | 25 June 2025

Evotec SE (Nasdaq: EVO) Joins NURTuRE-AKI Consortium to Advance Kidney Disease Research

Evotec SE (Frankfurt Stock Exchange: EVT; Nasdaq: EVO) has announced its participation in the NURTuRE-AKI consortium, a longitudinal research initiative focused on acute kidney injury (AKI) and its progression to chronic kidney disease (CKD). The study targets both adult and pediatric cardiac surgery patients …

Team Kalkine | 25 June 2025

WISeKey (Nasdaq: WKEY) Expands Satellite Access via Astrocast Agreement to Strengthen IoT Coverage

WISeKey International Holding Ltd (SIX: WIHN; Nasdaq: WKEY) announced that its subsidiary, WISeSat.Space, has signed a strategic collaboration agreement with Astrocast, a nanosatellite IoT network operator based in Switzerland. The agreement grants WISeSat access to Astrocast’s operational Low Earth Orbit (LEO) satellite constellation, significantly …

Team Kalkine | 25 June 2025

InspireMD (Nasdaq: NSPR) Receives FDA PMA Approval for CGuard Prime

InspireMD, Inc. (Nasdaq: NSPR), a medical technology company focused on stroke prevention, has received premarket approval (PMA) from the U.S. Food and Drug Administration (FDA) for its CGuard Prime Carotid Stent System. The approval allows the commercial launch of the device in the U.S. …

Team Kalkine | 25 June 2025

Coherent (NYSE: COHR) Launches ACE FL Thulium Fiber Laser for BPH and Kidney Stone Procedures

Coherent Corp. (NYSE: COHR) has announced the launch of its new ACE FL series thulium fiber laser (TFL), engineered for therapeutic medical applications such as lithotripsy (kidney stone treatment) and benign prostatic hyperplasia (BPH) procedures. The laser system is designed for integration into surgical …

Team Kalkine | 25 June 2025

Essent Group (NYSE: ESNT) Receives "Moderate Buy" Consensus from Brokerages

Shares ofEssent Group Ltd. (NYSE: ESNT)have received a"Moderate Buy"consensus rating from the seven brokerages currently tracking the stock, according to a report fromMarketBeat. The outlook reflects two analysts assigning a "Hold" rating and five assigning a "Buy" recommendation.

Team Kalkine | 24 June 2025

Raymond James Upgrades DoorDash (NASDAQ: DASH) to ‘Strong Buy’ Amid Deliveroo Acquisition

DoorDash Inc. (NASDAQ: DASH)received an upgraded stock rating fromRaymond Jameson Monday, with the brokerage citing significant upside from the company’s recently announced acquisition ofDeliveroo. The firm revised its rating from‘Outperform’ to ‘Strong Buy’, and raised its price target fromUSD 215 to USD 260, implying …

Team Kalkine | 24 June 2025
Support

Hi! How can we help you today?

Loading…